Harwin Peter Evan's Form 4 filing
Oruka Therapeutics, Inc. (ORKA) · filed Jul 1, 2026
- Accession no.
- 0001104659-26-080009
- Filed
- Jul 1, 2026, 9:30 PM ET
- Trade date
- Jul 1, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $300.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director, 10% Owner |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director, 10% Owner |
| Fairmount Funds Management LLCCIK 0001802528 | Director, 10% Owner |
| Kiselak TomasCIK 0001830177 | Director, 10% Owner |
| Fairmount Healthcare Co-Invest III L.P.CIK 0002009690 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Common Stock | CConversionAcquired | +3,553,410 | –F1 | – | 4,685,364 | Indirect | |
| Jul 1, 2026 | Common Stock | SSaleDisposed | −3,553,410 | $84.43 | −$300,014,406.3 | 1,131,954 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Common Stock | CConversionDisposed | −3,553,410 | $0.00 | $0 | 94,497 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.
Referenced by the price of 1 transaction in Table I.
Remarks
Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is also a Managing Member of Fairmount.